



Integrating Perinatal Mental Health into Standard Obstetric Care: Closing the Silent Gap in Maternal Mortality

Sarah Jenkins* and Oliver Crawford

Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom

***Corresponding author:** Sarah Jenkins, Nuffield Department of Women's & Reproductive Health, University of Oxford, Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom

Mini Review

Volume 9 Issue 2

Received Date: November 15, 2025

Published Date: December 21, 2025

Abstract

Perinatal depression and anxiety affect approximately 15% to 20% of women during pregnancy and the first postpartum year. Far from being a benign, self-limiting emotional fluctuation, perinatal mood disorders represent a leading underlying etiology of direct and indirect maternal mortality in high-income nations, with maternal suicide accounting for up to 20% of late postpartum maternal deaths. In low- and middle-income settings, perinatal mental illness remains deeply stigmatized, under-screened, and poorly managed, exacerbating intergenerational developmental impairments in offspring. The traditional paradigm of a single postpartum clinical visit at six weeks postpartum fails to capture acute mood crises that peak in the early and late postpartum periods. Recent approvals of rapid-acting neuroactive steroids targeting GABA-A receptors (such as zuranolone) provide powerful new pharmacological avenues; however, medication alone cannot solve fragmented care pathways. This editorial argues for mandatory universal perinatal mental health screening, embedding dedicated clinical psychologists within obstetric clinics, and dismantling insurance and systemic reimbursement hurdles for collaborative psychiatric maternity care.

Keywords: Perinatal Mental Health; Postpartum Depression; Maternal Mortality; Zuranolone; Universal Screening; Obstetric Collaborative Care

Abbreviations

PPD: Postpartum Depression; PMAD: Perinatal Mood and Anxiety Disorders; EPDS: Edinburgh Postnatal Depression Scale; GABA: Gamma-Aminobutyric Acid; MBRRACE: Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries.

The Silent Maternal Health Crisis

For decades, the global maternal health community has focused almost exclusively on the classic triad of obstetric

mortality: hemorrhage, sepsis, and hypertensive disorders of pregnancy. While vital progress has been achieved in acute surgical and pharmacological protocols, an equally lethal crisis has unfolded in the shadows: perinatal mental health disorders.

Data from confidential maternal mortality audits, including MBRRACE-UK and US Maternal Mortality Review Committees (MMRCs), reveal that psychiatric causes—predominantly suicide and substance-use overdose—constitute the leading cause of maternal death between 42 days and one year postpartum. Nearly 75% of women

experiencing perinatal mood and anxiety disorders (PMADs) remain completely undiagnosed and untreated.

The Failure of the Single Six-Week Postpartum Visit

The legacy standard of obstetric care—a single brief check-up at six weeks postpartum—is fundamentally ill-equipped to address perinatal mental health. Mood disruptions often manifest acutely in the first two weeks (early onset) or peak insidiously around 3 to 6 months postpartum as social support diminishes and sleep deprivation accumulates.

The American College of Obstetricians and Gynecologists (ACOG) has rightly called for 'redefining the fourth trimester' into a continuous, comprehensive paradigm. Yet, clinical practice has been slow to evolve. Universal screening with validated tools such as the Edinburgh Postnatal Depression Scale (EPDS) or PHQ-9 remains inconsistently applied across prenatal visits, delivery admissions, and pediatric well-child checks.

Therapeutic Innovations: The Rise of Neuroactive Steroids

A critical biological breakthrough in postpartum depression management has been the development of neuroactive steroids. Unlike conventional monoaminergic antidepressants (SSRIs/SNRIs) that require 4 to 8 weeks to achieve clinical remission, positive allosteric modulators of synaptic and extrasynaptic GABA-A receptors (e.g., zuranolone and brexanolone) target the rapid postpartum

withdrawal of allopregnanolone.

In randomized double-blind Phase 3 trials (the SKYLARK and ROBIN studies), a 14-day oral course of zuranolone (50 mg/day) achieved rapid, clinically meaningful reductions in depressive symptoms by Day 3, with sustained improvements through Day 45. This rapid onset of action is invaluable during the critical early bonding window between mother and infant.

A Call for a Multi-Tiered Collaborative Maternity Care Model

To genuinely close the perinatal mental health gap, our editorial board calls for three transformative systemic reforms:

- **Universal Multi-Point Screening:** Mandatory, reimbursement-supported EPDS screening at the initial prenatal intake, the third trimester (28-32 weeks), the hospital discharge post-delivery, and pediatric visits at 1, 2, 4, and 6 months.
- **Embedded Behavioral Health:** Implementing the Collaborative Care Model (CoCM), embedding perinatal mental health specialists directly into obstetric clinics rather than relying on external psychiatric referrals.
- **De-Stigmatization and Community Support:** National public health campaigns to normalize perinatal mental health challenges, paired with peer support groups and paid parental leave policies that relieve acute postpartum stressors.
- **Maternal health cannot be defined solely by physical survival;** psychological well-being is the cornerstone of thriving families and societies.